Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALCHEMIST
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.
- 15 Aug 2014 Planned primary completion date changed from 1 May 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.